(215 days)
Not Found
No
The description mentions a "microprocessor-controlled device" but does not include any terms or descriptions indicative of AI or ML, such as algorithms, learning, training data, or specific AI/ML functionalities.
Yes
The device is described as providing "fluid distension of the uterus during diagnostic and operative hysteroscopy," which is a direct therapeutic action as it enables medical procedures.
Yes
The "Intended Use / Indications for Use" section explicitly states that the device is "intended to provide fluid distension of the uterus during diagnostic and operative hysteroscopy." The mention of "diagnostic hysteroscopy" indicates its use in diagnostic procedures.
No
The device description clearly outlines multiple hardware components including pumps, scales, casing, power supply, cables, roller wheels, and tube sets. It is a physical system with integrated software control.
Based on the provided information, the Aquilex® Fluid Control System AQL-100S is not an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use is to provide fluid distension of the uterus and monitor fluid volume during hysteroscopy. This is a procedure performed in vivo (within the body) on a patient, not on a sample of biological material in vitro (outside the body).
- Device Description: The device is a pump and monitoring system designed to manage fluid flow during a surgical procedure. It does not involve the analysis of biological samples.
- Lack of IVD Characteristics: The description does not mention any components or functions related to analyzing blood, urine, tissue, or other biological specimens for diagnostic purposes.
IVD devices are specifically designed to examine specimens derived from the human body to provide information for the diagnosis, prevention, monitoring, treatment, or alleviation of disease. The Aquilex® system's function is procedural support during hysteroscopy, not diagnostic testing of biological samples.
N/A
Intended Use / Indications for Use
The Aquilex® Fluid Control System AQL-100S is intended to provide fluid distension of the uterus during diagnostic and operative hysteroscopy and to monitor the volume differential between the irrigation fluid flowing into and out of the uterus.
Product codes (comma separated list FDA assigned to the subject device)
HIG
Device Description
The Aquilex® Fluid Control System AQL-100S is a modified version of the primary predicate device, Aquilex Fluid Control System H112 (K112642). The proposed device is a microprocessor-controlled device that consists of the following two main components: (1) an irrigation pump unit including suction pumps (AQL-110P) and (2) and fluid monitoring unit (AQL-100CBS) that are to be placed on a roller stand. The irrigation pump unit (AQL-110P) of the Aquilex® Fluid Control System AQL-100S is a microprocessor-controlled device that functions according to the peristaltic principle and consists of the following components: (1) a casing. (2) a power switch, (3) a power supply, (4) mains cable, (5) a roller wheel, (6) a pump head, (7) suction pumps, (8) various setting keys and (9) display elements. The irrigation pump unit (AQL-110P) is to be used with specially designed single use irrigation and outflow tube sets that are delivered sterile (AQL-110 and AQL-111). In addition, the suction pumps of the irrigation pump unit are to be used with specially designed non-sterile vacuum tube sets (AQL-114). The fluid monitoring unit (AQL-100CBS) consists of the following main components: (1) two scale units, (2), a bag holder, (4) a bag deflector, (5) a container holder, and (6) a roller wheel base. The irrigation pump unit of the proposed device is only operational in conjunction with the fluid monitoring unit.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Uterus
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Electrical Safety and Electromagnetic Compatibility Testing: Electrical safety and electromagnetic compatibility testing was performed by independent laboratories and the test results demonstrate that the proposed device conforms to the below standards:
- IEC 60601-1 2005/(R)2012 and A1: 2012, C1:2009/(R)2012 andA2: ● 2010/(R)2012 (consolidated text); and
- IEC 60601-1-2 Fourth Edition: 2014.
Software: The software was considered as major level of concern in accordance with the FDA guidance document "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices". Software verification and validation testing of the Aquilex® Fluid Control System AQL-100S demonstrates that the device performs as intended. It was developed, tested and verified in accordance with the above FDA guidance document and in accordance with the following standard:
- IEC 62304 First Edition 2006-05. .
Biocompatibility: Biocompatibility testing was performed in accordance with:
- AAMI/ANSI/ISO 10993-1 Fourth Edition 2009-10-15 Biological . evaluation of medical devices- Evaluation and testing within a risk management system;
- . ISO 10993-5: 2009 (R) 2014 - Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity;
- . ISO 10993-10 Third Edition 2010-08-01 - Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization; and
- . ISO 10993-11 Second Edition 2006-08-15- Biological evaluation of medical devices -- Part 11: Tests for systemic toxicity;
- . ISO 10993-12:2007 Biological evaluation of medical devices -- Part 12: Sample preparation and reference materials.
Sterilization and Shelf Life: Sterilization validation was performed in accordance with:
- . ISO 10993-7 Second Edition 2008-10-15- Biological evaluation of medical devices - Part 7: Ethylene oxide sterilization residuals;
- . AAMI TIR 28 2009/(R)2013. Product adoption and process equivalency for ethylene oxide sterilization;
- ISO 11135-1:2007 Sterilization of health care products Ethylene oxide - Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices;
- . ISO 14937 Second Edition 2009-10-15- Sterilization of health care products - General criteria for characterization of a sterilizing agent and the development, validation and routine control of a sterilization process for medical devices.
Residual ethylene oxide (EO) and ethylene chlorohydrin (ECH) data shows that the limit of EO
§ 884.1700 Hysteroscopic insufflator.
(a)
Identification. A hysteroscopic insufflator is a device designed to distend the uterus by filling the uterine cavity with a liquid or gas to facilitate viewing with a hysteroscope.(b)
Classification. (1) Class II (performance standards).(2) Class I for tubing and tubing/filter fits which only include accessory instruments that are not used to effect intrauterine access, e.g., hysteroscopic introducer sheaths, etc.; and single-use tubing kits used for only intrauterine insufflation. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 884.9.
0
Image /page/0/Picture/0 description: The image contains the logos of the Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA). The HHS logo is on the left and features a stylized human figure. The FDA logo is on the right and includes the agency's acronym in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
February 5, 2018
W.O.M. World of Medicine GmbH % Susanne Raab Regulatory Consultant Susanne Raab Guenthersburgallee 75 60389 Frankfurt GERMANY
K172040 Re:
Trade/Device Name: Aquilex® Fluid Control System AOL-100S Regulation Number: 21 CFR 884.1700 Regulation Name: Hysteroscopic insufflator Regulatory Class: Class II Product Code: HIG Dated: January 3, 2018 Received: January 10, 2018
Dear Susanne Raab:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
1
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Joyce M. Whang -S
for
Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K172040
Device Name Aquilex® Fluid Control System AQL-100S
Indications for Use (Describe)
The Aquilex® Fluid Control System AQL-100S is intended to provide fluid distension of the uterus during diagnostic and operative hysteroscopy and to monitor the volume differential between the irrigation fluid flowing into and out of the uterus.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | ☑ |
|---|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) | □ |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows a logo with a circular shape at the top and the letters 'WOM' at the bottom. Inside the circle, there is a stylized design that resembles a figure eight or an infinity symbol. A small, red triangle is positioned at the bottom of the circular design, adding a pop of color to the logo. The overall design is simple and modern, with a focus on clean lines and geometric shapes.
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
General Information:
| Submitter: | W.O.M. WORLD OF MEDICINE GmbH
Salzufer 8
10587 Berlin
Germany
Phone: +49 30 39981 594
Fax: +49 30 39981 593 |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Registration Number: | 3001556604 |
| Contact Person: | Susanne Raab
Regulatory Consultant
Guenthersburgallee 75
60389 Frankfurt
Phone: 0049 69 28606161
e-mail: sbraab@comcast.net |
| Date Prepared: | January 30, 2018 |
| Proposed Device: | |
| Trade Name: | Aquilex® Fluid Control System AQL-100S |
| Common Name: | Hysteroscopic Insufflator, Fluid Monitoring
System and Tube Sets |
| Classification Name: | Hysteroscopic Insufflator and Accessories |
| Regulation Number: | 21 CFR 884.1700 |
| Regulation Name: | Hysteroscopic Insufflator |
| Regulatory Class: | II |
| Product Code: | HIG |
| Predicate Devices: | |
| Primary Predicate Device: | |
| Trade Name: | Aquilex Fluid Control System H112 |
| 510(k) Number: | K112642 |
| Applicant: | W.O.M. WORLD OF MEDICINE GmbH |
| Regulation Number: | 21 CFR 884.1700 |
| Regulatory Class: | II |
| Product Code: | HIG |
4
Secondary Predicate Device:
| Trade Name: | Hysteroscopy Pump HM6 |
|---|---|
| 510(k) Number: | K123732 |
| Applicant: | W.O.M. WORLD OF MEDICINE GmbH |
| Regulation Number: | 21 CFR 884.1700 |
| Regulatory Class: | II |
| Product Code: | HIG |
The predicate devices were not subject to a design-related recall.
Device Description:
The Aquilex® Fluid Control System AQL-100S is a modified version of the primary predicate device, Aquilex Fluid Control System H112 (K112642). The proposed device is a microprocessor-controlled device that consists of the following two main components: (1) an irrigation pump unit including suction pumps (AQL-110P) and (2) and fluid monitoring unit (AQL-100CBS) that are to be placed on a roller stand. The irrigation pump unit (AQL-110P) of the Aquilex® Fluid Control System AQL-100S is a microprocessor-controlled device that functions according to the peristaltic principle and consists of the following components: (1) a casing. (2) a power switch, (3) a power supply, (4) mains cable, (5) a roller wheel, (6) a pump head, (7) suction pumps, (8) various setting keys and (9) display elements. The irrigation pump unit (AQL-110P) is to be used with specially designed single use irrigation and outflow tube sets that are delivered sterile (AQL-110 and AQL-111). In addition, the suction pumps of the irrigation pump unit are to be used with specially designed non-sterile vacuum tube sets (AQL-114). The fluid monitoring unit (AQL-100CBS) consists of the following main components: (1) two scale units, (2), a bag holder, (4) a bag deflector, (5) a container holder, and (6) a roller wheel base. The irrigation pump unit of the proposed device is only operational in conjunction with the fluid monitoring unit.
Intended Use / Indication for Use:
The Aquilex® Fluid Control System AOL-100S is intended to provide fluid distension of the uterus during diagnostic and operative hysteroscopy and to monitor the volume differential between the irrigation fluid flowing into and out of the uterus.
5
Image /page/5/Picture/1 description: The image shows a logo for WOM. The logo consists of a circle with a stylized figure inside. The figure appears to be a person standing with their arms raised, and the lower part of the figure is colored in pink. The text "WOM" is written below the logo.
Substantial Equivalence and Comparison of Technological Characteristics:
The proposed device, Aquilex® Fluid Control System AQL-100S, is substantially equivalent to the predicate devices, Aquilex Fluid Control System H112 (K112642) and Hysteroscopy Pump HM6 (K123732). As stated above the proposed device, Aquilex® Fluid Control System AQL-100S, is a modified version of the primary predicate device, Aquilex Fluid Control System H112.
The proposed device, Aquilex® Fluid Control System AQL-100S, and the predicate devices, Aquilex Fluid Control System H112 and Hysteroscopy Pump HM6, are all intended to provide fluid distension of the uterus during diagnostic and operative hysteroscopy and to monitor the volume differential between the irrigation fluid flowing into and out of the uterus. The proposed device and the predicate devices have the same intended use.
Furthermore, tThe proposed device, Aquilex® Fluid Control System AQL-100S, and the predicate device, Aquilex Fluid Control System H112 and Hysteroscopy Pump HM6, use the same basic operating principles and incorporate the same basic design. All three devices incorporate the following main components: (1) irrigation pump, (2) fluid monitoring unit, (3) irrigation and outflow tube sets.
The modification to the Aquilex® Fluid Control System AQL-100S in comparison to the primary predicate device, Aquilex Fluid Control System H112, do not raise different questions of safety and effectiveness. The differences between both devices are the following:
- Incorporation of a separate bag scale into the fluid monitoring unit of the . Aquilex® Fluid Control System AQL-100S to calculate the inflow volume, whereas the Aquilex Fluid Control System H112 determines the inflow volume based on the number of rotation of the roller wheel.
- . Change in design of the cart to allow for a mounting of the bag scale and addition of bag deflector.
- . Incorporation of a fluid bag and container change detection feature into the Aquilex® Fluid Control System AQL-100S.
- . Increase in the suction pressure of the low suction pump from 125 to 225 mmHg.
- . The inflow tubing AQL-110 of the primary predicate device has been slightly modified.
6
Image /page/6/Picture/1 description: The image shows a logo for WOM. The logo consists of a gray circle with a stylized symbol inside. The symbol resembles an infinity sign above a pink triangle. Below the circle, the letters "WOM" are written in a simple, sans-serif font.
- · The filter of the reusable vacuum tubing is manufactured by a different supplier.
With regards to the incorporation of an additional bag scale, the proposed device, Aquilex® Fluid Control System AQL-100S, is substantially equivalent to the secondary predicate device, Hystersocopy Pump HM6, that also utilizes a separate scale for determination of the inflow volume.
With regards to the incorporation of a separate bag scale into the fluid monitoring unit to determine the inflow volume and change in design of the cart to allow for a mounting of the bag scale, the proposed device, Aquilex® Fluid Control System AQL-100S, is substantial equivalent to the secondary predicate device, Hysteroscopy Pump HM6. Like the proposed device, Aquilex® Fluid Control System AQL-100S, the secondary predicate device, Hysteroscopy Pump HM6, incorporates a separate scale to determine the inflow volume for calculation of the fluid deficit.
With regards to the fluid bag change detection feature is substantially equivalent to the secondary predicate device, Hysteroscopy Pump HM6, that incorporates the same feature. The bag deflector was added to the fluid monitoring unit of the proposed device. Aquilex® Fluid Control System AOL-100S. to protect the bag scale from fluid.
The increase in the suction pressure of the suction pump from 125 to 225 mmHg, that was implemented due to end user demand to ensure fluid suction even if the tubing is draped over the patient's leg.
The modifications that were made on the inflow tubing AQL-110 are minor and have not changed the material, suppliers and manufacturing method.
Performance Data:
Electrical Safety and Electromagnetic Compatibility Testing:
Electrical safety and electromagnetic compatibility testing was performed by independent laboratories and the test results demonstrate that the proposed device conforms to the below standards:
- IEC 60601-1 2005/(R)2012 and A1: 2012, C1:2009/(R)2012 andA2: ● 2010/(R)2012 (consolidated text); and
- IEC 60601-1-2 Fourth Edition: 2014.
7
Image /page/7/Picture/0 description: The image shows a logo for WOM. The logo consists of a circle with a stylized figure inside, resembling a person with arms raised. The figure is positioned above the letters "WOM" in a sans-serif font. The figure is colored in pink, while the circle and the letters are in gray.
Software:
The software was considered as major level of concern in accordance with the FDA guidance document "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices". Software verification and validation testing of the Aquilex® Fluid Control System AQL-100S demonstrates that the device performs as intended. It was developed, tested and verified in accordance with the above FDA guidance document and in accordance with the following standard:
- IEC 62304 First Edition 2006-05. .
Biocompatibility:
Biocompatibility testing was performed in accordance with:
- AAMI/ANSI/ISO 10993-1 Fourth Edition 2009-10-15 Biological . evaluation of medical devices- Evaluation and testing within a risk management system;
- . ISO 10993-5: 2009 (R) 2014 - Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity;
- . ISO 10993-10 Third Edition 2010-08-01 - Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization; and
- . ISO 10993-11 Second Edition 2006-08-15- Biological evaluation of medical devices -- Part 11: Tests for systemic toxicity;
- . ISO 10993-12:2007 Biological evaluation of medical devices -- Part 12: Sample preparation and reference materials.
Sterilization and Shelf Life:
Sterilization validation was performed in accordance with:
- . ISO 10993-7 Second Edition 2008-10-15- Biological evaluation of medical devices - Part 7: Ethylene oxide sterilization residuals;
- . AAMI TIR 28 2009/(R)2013. Product adoption and process equivalency for ethylene oxide sterilization;
8
Image /page/8/Picture/1 description: The image shows a logo for WOM. The logo consists of a circle with a stylized symbol inside, resembling a person with arms raised. The symbol is partially colored in pink. Below the symbol, the letters "WOM" are written in a sans-serif font.
- ISO 11135-1:2007 Sterilization of health care products Ethylene oxide - Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices;
- . ISO 14937 Second Edition 2009-10-15- Sterilization of health care products - General criteria for characterization of a sterilizing agent and the development, validation and routine control of a sterilization process for medical devices.
Residual ethylene oxide (EO) and ethylene chlorohydrin (ECH) data shows that the limit of EO